Humana Reports 2025 Financials, Details Significant Regulatory Headwinds & New Acquisition

summarizeSummary

Humana's 2025 annual report reveals a slight dip in net income and EPS despite revenue growth, overshadowed by significant regulatory challenges including declining Medicare Advantage Star Ratings and ongoing RADV audit litigation, alongside a recent primary care acquisition.

check_boxKey Events

• 2025 Financial Performance

  Humana reported a net income attributable to Humana of $1.188 billion ($9.84 diluted EPS) for 2025, a slight decrease from $1.207 billion ($9.98 diluted EPS) in 2024, despite a 10.1% increase in total revenues to $129.664 billion. The benefit ratio increased to 90.2% and the operating cost ratio rose to 12.0%.

• Medicare Advantage Star Ratings Decline

  The number of Humana's Medicare Advantage plans rated 4-star or higher significantly declined in 2025, which is expected to negatively impact 2026 quality bonus payments from CMS. A lawsuit filed to vacate these ratings was initially successful but is now under government appeal.

• Ongoing RADV Audit Lawsuit

  The company is engaged in a lawsuit against CMS regarding the elimination of the Fee-for-Service Adjuster in RADV audits. While a court granted summary judgment to Humana in September 2025, vacating the Final RADV Rule, the government appealed this decision in November 2025, maintaining significant uncertainty and potential financial impact from expanded audits for payment years 2018-2024.

• New Primary Care Business Acquisition

  On February 13, 2026, Humana completed the acquisition of a primary care business for approximately $941 million, expanding its CenterWell segment.

auto_awesomeAnalysis

Humana's 2025 annual report provides a comprehensive overview of its financial performance and strategic direction, highlighting several critical challenges. While the company achieved notable revenue growth, net income and diluted EPS saw a slight decline, partly due to significant value creation initiatives and impairment charges. The most impactful disclosures relate to the regulatory environment, particularly the significant decline in Medicare Advantage plans rated 4-star or higher, which will directly reduce 2026 quality bonus payments. The ongoing legal battle against CMS's RADV audit methodology, despite an initial favorable ruling that is now under appeal, introduces substantial financial uncertainty. Multiple other lawsuits, including a stockholder class action and a DOJ qui tam action, further elevate the company's legal and operational risks. Strategically, the company exited unprofitable Medicare Advantage plans in 2025, anticipating a rebound in membership growth for 2026, and completed a notable primary care business acquisition in February 2026. Investors should closely monitor the outcomes of the various legal and regulatory challenges, as they pose material risks to future profitability and operational stability.